Phase II evaluation of dacarbazine (D), mitomycin-C (M), doxorubicin (A) and cisplatin (P) (DMAP) plus sargramostim (GM-CSF) in the treatment of advanced, persistent, or recurrent leiomyosarcoma of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback